Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04690920

Enrollment

200

Registered

2020-12-31

Start date

2020-07-23

Completion date

2020-12-10

Last updated

2020-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Disease 2019 (COVID-19)

Keywords

corona virus disease 2019 (COVID-19), Tocilizumab, Remdesivir, Interleukin receptor-6, glycoprotein-130, receptor blocker

Brief summary

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Interventions

DRUGTocilizumab

Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy

Exclusion criteria

Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent

Design outcomes

Primary

Measure	Time frame
Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen	7 days

Secondary

Measure	Time frame	Description
Hospital stay	15 days	—
Oxygen demand	7-15 days	—
Viral load	7-15 days	by RT-PCR

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026